Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Sets up US subsidiary

YORK, UK -- (Marketwire) -- 11/26/12 --






          Tissue Regenix sets up United States subsidiary
           to target growing regenerative medicine market

Tissue Regenix appoints Greg Bila President, Tissue Regenix USA

YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has
set up a subsidiary company in the United States, as part of its
commercialisation strategy for its dCELL® technology platform.

Tissue Regenix is also pleased to announce the recruitment of Greg Bila
from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA.
Greg's recent career at KCI has spanned a number of sales & marketing
roles and brings over 20 years' experience in pharmaceutical and
medical device fields.

Tissue Regenix will use its patented dCELL® technology to target a
number of areas. Work will focus initially on applying the dCELL® to
the treat a number of chronic diseases but, over time, could be
developed for other applications including vascular repair, heart valve
replacement and knee repair. Tissue Regenix's dCELL® technology have
delivered encouraging interim data.

Antony Odell, Managing Director of Tissue Regenix commented: "This is a
significant step in the development of Tissue Regenix. It is an
excellent signal of the strength of TR's proposition that we can
attract people of Greg's calibre and experience, we look forward to
advancing our plans in the US with him at the helm. The United States
presents an opportunity to establish our platform dCELL® technology in
a market potentially worth hundreds of millions of dollars."

Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am
excited to be able to join Tissue Regenix at the beginning of its
expansion into the United States. TR's dCELL® technology will be a
welcome offering for the treatment of number of diseases and the
potential indications are attractive."

The potential advantages of the Company's dCELL technology over other
types of decellularised tissue scaffolds was underpinned at Tissue
Regenix technology day in October by Dr Alan Dardik, Associate
Professor of Surgery at Yale University, who has conducted pre-clinical
studies of Tissue Regenix dCELL® vascular patch and published the
results in the scientific journal PLoS ONE.

Speaking about those studies Dr Dardik commented: "I have to say my
impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are trying
to attract stem-cells but they've already got the stem cells that are
coming into their patch."



ENDS


For Further Information

Tissue Regenix Group plc:         01904 435 176
Antony Odell

Newgate Communications:
Alistair Kellie                   07801 234598
Andrew Adie                       07970 256512
Martin Greig                      07584 221513





About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation
('dCELL®) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which is
not rejected by the patient's body which can then be used to repair
diseased or worn out body parts. The potential applications of this
process are diverse and address many critical clinical needs such as
vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
Silver shows that predictions in areas such as economics have been less successful, e.g. he examines why many economists missed the recession, and why supposedly expert forecasters get election predictions wrong so often. For example, before the recession of 2008, the assumption was ma...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
You can then easily piece together full transaction traces by ordering all method calls by sequence number. Further analysis can be applied to this information for a number of purposes. For example, by analysing the transactions, developers can easily construct design diagrams that can...
Every day and every second, the system administrator gets tones of information on the network operation, network devices’ operation, and messages from users; he sets dozens of challenges, which must help to avoid the existing and possible problems in the future. Often, it is rather dif...
With the increasing complexity of software, organizations are more cognizant than ever about the potential pitfalls of including open source code in their products. Below are some quick tips to continue leveraging open source code, while keeping your manager and legal department happy.
The industry is heated with debates on whether adopting private or public cloud is the smartest, best, cheapest, you name it choice. But this debate is missing the mark. Businesses shouldn’t be discussing public vs. private, but rather how can they make the two work together to their g...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE